AU2021227007A1 - Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid - Google Patents
Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid Download PDFInfo
- Publication number
- AU2021227007A1 AU2021227007A1 AU2021227007A AU2021227007A AU2021227007A1 AU 2021227007 A1 AU2021227007 A1 AU 2021227007A1 AU 2021227007 A AU2021227007 A AU 2021227007A AU 2021227007 A AU2021227007 A AU 2021227007A AU 2021227007 A1 AU2021227007 A1 AU 2021227007A1
- Authority
- AU
- Australia
- Prior art keywords
- alpelisib
- compound
- pharmaceutically acceptable
- cancer
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305190 | 2020-02-27 | ||
| EP20305190.9 | 2020-02-27 | ||
| PCT/EP2021/054815 WO2021170793A1 (en) | 2020-02-27 | 2021-02-26 | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021227007A1 true AU2021227007A1 (en) | 2022-10-20 |
Family
ID=69784379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021227007A Abandoned AU2021227007A1 (en) | 2020-02-27 | 2021-02-26 | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12427142B2 (https=) |
| EP (1) | EP4110326B1 (https=) |
| JP (1) | JP2023516951A (https=) |
| KR (1) | KR20220146473A (https=) |
| CN (1) | CN115209893B (https=) |
| AR (1) | AR121589A1 (https=) |
| AU (1) | AU2021227007A1 (https=) |
| BR (1) | BR112022015972A2 (https=) |
| CA (1) | CA3168936A1 (https=) |
| IL (1) | IL295807A (https=) |
| MX (1) | MX2022010539A (https=) |
| TW (1) | TW202146007A (https=) |
| WO (1) | WO2021170793A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021003440A2 (pt) | 2018-09-07 | 2021-05-18 | Sanofi | sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação |
| EP4037768B1 (en) | 2019-10-01 | 2023-10-11 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| AU2020399168A1 (en) | 2019-12-09 | 2022-07-28 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| TW202233572A (zh) | 2020-10-19 | 2022-09-01 | 法商賽諾菲公司 | 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途 |
| WO2022084280A1 (en) | 2020-10-19 | 2022-04-28 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1752792A (en) | 1991-03-08 | 1992-10-06 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
| DE19833786A1 (de) | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EP1229036B1 (en) | 2001-01-24 | 2005-01-12 | CHIESI FARMACEUTICI S.p.A. | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| PL374215A1 (en) | 2001-08-11 | 2005-10-03 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
| DK1501819T3 (da) | 2002-04-24 | 2011-01-10 | Merck Sharp & Dohme | Østrogenreceptormodulatorer |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| WO2006012135A1 (en) | 2004-06-24 | 2006-02-02 | Janssen Pharmaceutica, N. V. | Quaternary salt ccr2 antagonists |
| ES2551086T3 (es) | 2005-06-14 | 2015-11-16 | Baylor University | Análogos de combretastatina con actividad de unión a tubulina |
| US8127618B1 (en) | 2007-05-18 | 2012-03-06 | Pacesetter, Inc. | Implantable micro-electromechanical system sensor |
| EP2048126A1 (de) | 2007-10-11 | 2009-04-15 | Bayer Schering Pharma AG | Benzocycloheptanderivate als selektiv wirksame Estrogene |
| WO2009101634A2 (en) | 2008-02-13 | 2009-08-20 | Lupin Limited | A novel process for the preparation of eszopiclone |
| DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2012068284A2 (en) | 2010-11-16 | 2012-05-24 | Baylor University | Efficient method for preparing functionalized benzosuberenes |
| CA2819299A1 (en) | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| WO2013097773A1 (en) | 2011-12-30 | 2013-07-04 | Centaurus Biopharma Co., Ltd. | Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators |
| CN102584687A (zh) | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
| CN105828822B (zh) | 2013-08-14 | 2019-10-18 | 诺华股份有限公司 | 用于治疗癌症的组合疗法 |
| WO2015028409A1 (de) | 2013-08-27 | 2015-03-05 | Bayer Pharma Aktiengesellschaft | 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| EP3089747A1 (en) | 2013-12-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
| KR102598782B1 (ko) | 2014-10-03 | 2023-11-07 | 노파르티스 아게 | 알펠리십을 포함하는 제약 조성물 |
| WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| TWI874834B (zh) | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| KR20250152679A (ko) | 2015-04-29 | 2025-10-23 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| US10144728B2 (en) * | 2015-10-06 | 2018-12-04 | Dow Agrosciences Llc | Alkylation of picolinamides with substituted chloroacylals utilizing a crown ether catalyst |
| CN106924210A (zh) | 2015-12-29 | 2017-07-07 | 北京新领先医药科技发展有限公司 | 一种含有帕布昔利布的胶囊剂及其制备方法 |
| EA034994B1 (ru) * | 2016-02-15 | 2020-04-15 | Санофи | 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов |
| ES3039455T3 (en) | 2016-11-17 | 2025-10-21 | Sanofi Sa | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| CN111386113A (zh) | 2017-12-01 | 2020-07-07 | 诺华股份有限公司 | 包含lsz102和阿培利司的药物组合 |
| CN109896991B (zh) | 2017-12-08 | 2020-11-20 | 苏州远智医药科技有限公司 | 一种δ阿片受体拮抗剂及其用途和药物组合物 |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| BR112021003440A2 (pt) | 2018-09-07 | 2021-05-18 | Sanofi | sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação |
| AU2019379179A1 (en) | 2018-11-16 | 2021-06-10 | Arqule, Inc. | Pharmaceutical combination for treatment of cancer |
| MX2021005876A (es) | 2018-11-30 | 2021-07-16 | Radius Pharmaceuticals Inc | Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama. |
| CA3146346A1 (en) | 2019-05-09 | 2020-11-12 | Sanofi | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients |
| EP4037768B1 (en) | 2019-10-01 | 2023-10-11 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| AU2020399168A1 (en) | 2019-12-09 | 2022-07-28 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| EP4069225A4 (en) * | 2019-12-20 | 2023-12-27 | Recurium IP Holdings, LLC | COMBINATIONS |
| CA3169679A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| WO2022084280A1 (en) | 2020-10-19 | 2022-04-28 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| TW202233572A (zh) | 2020-10-19 | 2022-09-01 | 法商賽諾菲公司 | 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途 |
| WO2022106711A1 (en) | 2020-11-23 | 2022-05-27 | Sanofi | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| TW202304425A (zh) | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合 |
| TW202304424A (zh) | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含依維莫司和安森司群的組合 |
-
2021
- 2021-02-25 TW TW110106633A patent/TW202146007A/zh unknown
- 2021-02-26 KR KR1020227029446A patent/KR20220146473A/ko not_active Withdrawn
- 2021-02-26 MX MX2022010539A patent/MX2022010539A/es unknown
- 2021-02-26 CA CA3168936A patent/CA3168936A1/en active Pending
- 2021-02-26 BR BR112022015972A patent/BR112022015972A2/pt not_active Application Discontinuation
- 2021-02-26 EP EP21707690.0A patent/EP4110326B1/en active Active
- 2021-02-26 WO PCT/EP2021/054815 patent/WO2021170793A1/en not_active Ceased
- 2021-02-26 US US17/802,223 patent/US12427142B2/en active Active
- 2021-02-26 JP JP2022551616A patent/JP2023516951A/ja active Pending
- 2021-02-26 IL IL295807A patent/IL295807A/en unknown
- 2021-02-26 CN CN202180017056.6A patent/CN115209893B/zh active Active
- 2021-02-26 AU AU2021227007A patent/AU2021227007A1/en not_active Abandoned
- 2021-02-26 AR ARP210100523A patent/AR121589A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20230089371A1 (en) | 2023-03-23 |
| CA3168936A1 (en) | 2021-09-02 |
| EP4110326A1 (en) | 2023-01-04 |
| WO2021170793A1 (en) | 2021-09-02 |
| CN115209893B (zh) | 2024-08-30 |
| US12427142B2 (en) | 2025-09-30 |
| BR112022015972A2 (pt) | 2022-10-11 |
| IL295807A (en) | 2022-10-01 |
| TW202146007A (zh) | 2021-12-16 |
| EP4110326B1 (en) | 2024-01-31 |
| CN115209893A (zh) | 2022-10-18 |
| MX2022010539A (es) | 2022-09-21 |
| JP2023516951A (ja) | 2023-04-21 |
| EP4110326C0 (en) | 2024-01-31 |
| AR121589A1 (es) | 2022-06-22 |
| KR20220146473A (ko) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12427142B2 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| US20240197739A1 (en) | Combination Comprising Ribociclib and Amcenestrant | |
| US20230404971A1 (en) | Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid | |
| ES3036485T3 (en) | Combination comprising everolimus and amcenestrant | |
| KR20240112932A (ko) | 암 치료를 위한 cdk2 억제제 및 cdk4 억제제를 포함하는 방법 및 투여 섭생법 | |
| US20230038138A1 (en) | Combination therapy for treating cancer | |
| EP4203963A1 (en) | Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| US20250222003A1 (en) | Pharmaceutical composition for treating solid tumors | |
| HK40110657A (zh) | 用於治疗癌症的cdk4抑制剂 | |
| CN117580572A (zh) | 用安森司坦和帕博西尼治疗乳腺癌 | |
| CN120302974A (zh) | 喹诺林化合物治疗甲状腺癌的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |